Overview: A New Chapter in HIV Prevention A long-awaited option for preventing HIV infection is moving closer to routine use in England and Wales. Cabotegravir (CAB-LA), a long-acting injectable that is administered every two months, is poised to become the first injectable form of PrEP (pre-exposure prophylaxis) approved by the National Institute for Health and…